| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.04. | KINETA, INC./DE - 8-K, Current Report | 2 | SEC Filings | ||
| 08.04. | Kineta jumps on positive early-stage tumor treatment trial | 2 | Reuters | ||
| 08.04. | Kineta, Inc.: Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial | 134 | GlobeNewswire (Europe) | Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety and tolerability profile observed with no dose... ► Artikel lesen | |
| 08.04. | KINETA, INC./DE - 8-K, Current Report | 1 | SEC Filings | ||
| 21.03. | Kineta GAAP EPS of -$1.28 beats by $0.12, revenue of $5.44M misses by $0.15M | 1 | Seeking Alpha | ||
| 21.03. | KINETA, INC./DE - 10-K, Annual Report | 1 | SEC Filings | ||
| 21.03. | Kineta, Inc.: Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update | 122 | GlobeNewswire (Europe) | Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts in the VISTA-101 trial No dose limiting toxicities observed at any dose... ► Artikel lesen | |
| 21.03. | KINETA, INC./DE - 8-K, Current Report | 1 | SEC Filings | ||
| 12.03. | KINETA, INC./DE - 8-K, Current Report | 1 | SEC Filings | ||
| 29.02. | Kineta Restructures to Prioritize Cash, Explores Strategic Options | 2 | Contract Pharma | ||
| 29.02. | Kineta Inc to explore strategic alternatives, shares fall | 4 | Reuters | ||
| 29.02. | Kineta cuts workforce, CEO steps down amid restructuring | 3 | Investing.com | ||
| 29.02. | After saving Yumanity's assets, Kineta faces shutdown as private placement fails to show up | 2 | FierceBiotech | ||
| 29.02. | Kineta stock falls ~25.7% after co cuts workforce by 64%, including CEO | 4 | Seeking Alpha | ||
| 29.02. | KINETA, INC./DE - 8-K, Current Report | 2 | SEC Filings | ||
| 22.02. | Kineta, Inc.: Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium | 1 | GlobeNewswire (USA) | ||
| 14.02. | Kineta, Inc.: Kineta to Present at Upcoming Investor Conferences | 1 | GlobeNewswire (USA) | ||
| 17.01. | Kineta Issues Update On Phase 1/2 VISTA-101 Trial Of KVA12123 | - | RTTNews | ||
| 17.01. | Kineta, Inc.: Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors | 395 | GlobeNewswire (Europe) | Cleared First Four Monotherapy Doses and Initial Combination Cohort with No Dose Limiting Toxicities at any Dose Level KVA12123 Monotherapy Demonstrated Dose Proportional Induction of Pro-inflammatory... ► Artikel lesen | |
| 17.01. | KINETA, INC./DE - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| GAMESTOP | 4.522 |
| PLUG POWER | 4.291 |
| EVOTEC | 4.123 |
| TUI | 3.985 |
| BAYER | 3.304 |
| NEL | 3.279 |
| AMC ENTERTAINMENT | 2.802 |
| RHEINMETALL | 2.249 |
| ALIBABA | 1.488 |
| NORDEX | 1.433 |
| DELIVERY HERO | 1.338 |
| MERCEDES-BENZ | 1.244 |
| COMMERZBANK | 1.223 |
| SIEMENS ENERGY | 1.157 |
| BYD | 1.151 |
| NVIDIA | 1.150 |
| ALLIANZ | 1.149 |
| RWE | 1.102 |
| AIXTRON SE | 1.091 |
| THYSSENKRUPP | 987 |
| DEUTSCHE BANK | 934 |
| VOLKSWAGEN | 901 |
| DEUTSCHE PFANDBRIEFBANK | 856 |
| NOVAVAX | 816 |
| THYSSENKRUPP NUCERA | 808 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
